Drug Profile
Research programme: CNS disorder therapeutics - Servier/VECT-HORUS
Alternative Names: CNS therapeuticsLatest Information Update: 05 Jul 2021
Price :
$50
*
At a glance
- Originator Servier; VECT-HORUS
- Class Drug conjugates; Neuroprotectants; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research CNS disorders
Most Recent Events
- 05 Jul 2021 Early research is ongoing in CNS disorders in France (unspecified route) (VECT-HORUS pipeline, July 2021)
- 28 Aug 2020 No recent reports of development identified for research development in CNS-disorders in France
- 09 Sep 2016 VECT-HORUS and Servier enter a collaborative agreement to co-develop drugs for CNS disorder therapeutics in France